Skip Navigation
Search Menu

 
Print This Page
Share this page: More
 

Bloomberg~Kimmel Institute for Cancer Immunotherapy

immunotherapy

Two familiar names are cementing the Kimmel Cancer Center’s ability to continue its groundbreaking laboratory and clinical advances in cancer immunology. Sidney Kimmel, for whom the Kimmel Cancer Center is named, and three-term New York city mayor Michael Bloomberg are each contributing $50 million over five years to establish the Bloomberg/Kimmel Institute for Cancer Immunotherapy. As a result of the two lead gifts from Kimmel and Bloomberg, additional money has been raised toward the goal of $125 million for the first five years.

Kimmel and Bloomberg have a long history of support for Johns Hopkins. Since 2001, Kimmel has contributed $157 million, and the Johns Hopkins cancer center is named in his honor. Kimmel has given an additional $2.4 million to support 12 young cancer scientists at Johns Hopkins as part of the national Kimmel Scholars Program. Bloomberg is a 1964 alumnus of the Johns Hopkins University and was chairman of its board of trustees from 1996 to 2002. He has given $1.2 billion to the University and Johns Hopkins Health System since graduating. The Johns Hopkins Bloomberg School of Public Health and Charlotte R. Bloomberg Children’s Center are among the facilities named to honor his contributions.

Cancer immune therapy is one of the most promising areas of cancer research. It makes cancer cells visible to immune cells and causes the immune system to take action against cancer. (Read The Final Frontier, page 3 for breakthrough immune therapy discoveries by Kimmel Cancer Center scientists.)

Internationally recognized immunology expert Drew Pardoll, M.D., Ph.D., will serve as the Institute’s director. Pardoll is a veteran scientist whose career in immunology and cancer research spans more than 25 years. The Bloomberg/Kimmel Institute will support cancer immunology research across many cancer types, including melanoma and colon, pancreatic, urologic, lung, breast, and ovarian cancers.

What is Immunotherapy: Bloomberg~Kimmel Institute for Cancer Immunotherapy

Drew Pardoll, M.D., Ph.D., Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Co-Director of the Cancer Immunology Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center explains what is immunotherapy and how it is changing cure rates for cancer patients.

Cancer Immunotherapy - Patient Perspective

Metastatic colon cancer patient, Stefanie tells her success story with immunotherapy and how it saved her life.

Learn more aboaut the Bloomberg~Kimmel Institute for Cancer Immunotherapy

Learn more about Immunotherapy and research at Johns Hopkins Kimmel Cancer Center.


 

 


A Special Program of Research: Promise and Progress at the Bloomberg~Kimmel Institute for Cancer Immunotherapy

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

NCI CCC